Navigation Links
VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
Date:9/24/2008

- Top-line Data to be Released Concurrent with November 9 AHA Data

Presentations -

SAN FRANCISCO, Sept. 24 /PRNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease, announced today that it has completed the last patient visit in its Phase 2 acute coronary syndrome (ACS) study, including the sub-study of patients who received an additional 3 months of treatment followed by a multi-detector computed tomography (MDCT) scan. VIA will report top-line data from the ACS trial, as well as the Phase 2 carotid endarterectomy trial (CEA), concurrent with the company's data presentations at the American Heart Association (AHA) Scientific Session 2008 on November 9.

VIA-2291 is a potent small molecule drug that targets inflammation in the blood vessel wall, a primary disease process in atherosclerosis. It is being developed as a once-daily, oral drug to potentially decrease the risk of major adverse cardiac events associated with inflammation, including heart attack and stroke.

The ACS principal study enrolled 191 patients, including more than 90 patients in the MDCT sub-study. The study is designed to establish dose and safety data in patients with ACS who have experienced a recent heart attack or unstable angina. The study includes measures of leukotrienes, biomarkers of inflammation, as well as medical imaging of the coronary vessels to evaluate the impact on plaque characteristics in a subset of patients. Patients in the study are treated once daily with one of three dose levels of VIA-2291 or placebo.

In addition to the ACS and CEA studies, VIA is conducting a third Pha
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... WOODCLIFF LAKE, N.J. and SAN DIEGO ... Pharmaceuticals, Inc. (NASDAQ: ARNA ) announced today that ... Phase 3 trials of lorcaserin entitled, "Early Weight Loss While ... 52 Weight-Loss Outcomes," was recently published in the online issue ... The Obesity Society. The objective of these analyses was to ...
(Date:7/30/2014)... , July 30, 2014  Lightlake Therapeutics Inc. ... treatments based on its expertise in opioid antagonists, ... commitment from a prominent international research and development ... on promoting innovative research-based initiatives, including those addressing ... spray for the delivery of naloxone that could ...
(Date:7/30/2014)... July 30, 2014   Medical Equipment Solutions, Corp. ... awarded a Department of Defense (US Army) contract valued ... a mobile MRI diagnostic machine and technical support staffing. ... through the Small Business Administration (SBA), Medical Equipment is ... with the latest medical diagnostic equipment. The SBA 8-A ...
Breaking Medicine Technology:Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3Medical Equipment Solutions Corp. Awarded $2 Million contract To Service DoD 2
(Date:7/30/2014)... 30, 2014 The Restore My Blood Sugar ... high blood sugar levels can now find an amazingly successful ... new program was created by D. Chao and Andrew Forester ... for patients when it comes to normalizing blood sugar levels. ... is a secret to the cure of diabetes that all ...
(Date:7/30/2014)... Sugar Land, TX (PRWEB) July 30, 2014 ... pharmacy recently announced their plans to move to a new ... been announced, but they will be moving soon. , MedX ... 6302 W Broadway in Pearland, TX 77581. This is the ... than their current one and will include a drive thru ...
(Date:7/30/2014)... 30, 2014 Conducting Advanced Root ... Thinking Skills and Innovative Techniques to Improve the ... and FDAnews**, Sept. 17-18, 2014 – Raleigh, NC, ... #1 reason for 483 observations since 1997. , ... a successful CAPA program has never been more ...
(Date:7/30/2014)... main drug to treat malaria, is now widespread ... ( P. falciparum ) parasites that cause ... genetic mutation in the parasites. However, a six-day ... standard three-day coursehas proved highly effective in treating ... in the New England Journal of Medicine ...
(Date:7/30/2014)... 2014 (HealthDay News) -- It can happen in an instant: ... or computer monitor and gets critically injured when the furniture ... child should look around their homes and imagine what could ... it is better than it becoming a reality," Dr. Alex ... in a college news release. Between 2009 and 2011, ...
Breaking Medicine News(10 mins):Health News:Restore My Blood Sugar Review Reveals Exclusive Ways to Normalize Blood Sugar 2Health News:MedX Pharmacy Relocates to New Facility 2Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 2Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 3Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 4Health News:Resistance to key malaria drug spreading at alarming rate in Southeast Asia 2Health News:Tip-Over Furniture Can Kill Kids 2
... , , HARRISBURG, Pa., Aug. ... across the state on the new Integrated Care Initiative, an effort ... and Medicaid issues. , , The new health ... create a single source for consumers to work with both agencies, ...
... , MINNEAPOLIS, Aug. 4 Court ordered Class ... USA, Inc. , et al. , court File No. 27-CV-01-18042 (action filed ... in Minnesota at any time before November 30, 2004, ... A class action lawsuit involving the marketing, advertising and promotion of Marlboro ...
... , , PALO ... launch of the PEAK((R)) PlasmaBlade TnA (Tonsil and Adenoid) tissue dissection ... (FDA). This new product is indicated for cutting and coagulation of ... removal of the tonsils and adenoids. , , ...
... , ATLANTA, Aug. 4 M2SYS ... today that GHG Corporation, an innovative time tracking software provider, ... software solution. , , Bio-SnapON(TM) allows GHG ... time tracking software, known as "eTSS," to eliminate buddy punching ...
... ... introduced a new technology offering including their new Scoreboard application. The ... a glance screen showing key business indicators updated in real-time. Data ... both. The Scoreboard will be available to clients that either license ...
... NEW YORK, Aug. 4 EVO Merchant Services, a leader ... the Ernst & Young Entrepreneur Of The Year ((R)) 2009 ... LLP, the award recognizes outstanding entrepreneurs who are building and leading ... of judges, and the award was presented at a gala event ...
Cached Medicine News:Health News:Pennsylvania Department of Aging Seeks Consumer Input on New Health Care Option 2Health News:Class Action Notice for Minnesota Light Cigarette Litigation From Lommen, Abdo, Cole, King & Stageberg, P.A. 2Health News:Class Action Notice for Minnesota Light Cigarette Litigation From Lommen, Abdo, Cole, King & Stageberg, P.A. 3Health News:PEAK Surgical Introduces PEAK PlasmaBlade(TM) TnA 2Health News:PEAK Surgical Introduces PEAK PlasmaBlade(TM) TnA 3Health News:M2SYS Biometric Software Solution Selected By GHG Corporation 2Health News:DME Billing Lets Home Care Providers Know How They are Doing in Real Time 2Health News:DME Billing Lets Home Care Providers Know How They are Doing in Real Time 3Health News:EVO Merchant Services, CEO, Ray Sidhom Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Winner in Metro New York 2Health News:EVO Merchant Services, CEO, Ray Sidhom Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Winner in Metro New York 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: